Positive News Sentiment NYSE:MYOV Myovant Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Myovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $12.96 +0.53 (+4.26%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$12.27▼$12.9950-Day Range$7.78▼$13.7752-Week Range$7.67▼$27.43Volume397,916 shsAverage Volume805,586 shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$16.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Myovant Sciences Stock Forecast (MarketRank)Analyst RatingHold2.33 Rating ScoreUpside/Downside28.6% Upside$16.67 Price TargetShort InterestHealthy10.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$192.08 K Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.45) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.69 out of 5 starsMedical Sector936th out of 1,428 stocksPharmaceutical Preparations Industry462nd out of 682 stocks 3.2 Analyst's Opinion Consensus RatingMyovant Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.67, Myovant Sciences has a forecasted upside of 28.6% from its current price of $12.96.Amount of Analyst CoverageMyovant Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.28% of the float of Myovant Sciences has been sold short.Short Interest Ratio / Days to CoverMyovant Sciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Myovant Sciences has recently decreased by 7.48%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMyovant Sciences does not currently pay a dividend.Dividend GrowthMyovant Sciences does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MYOV. Previous Next 3.3 News and Social Media Coverage News SentimentMyovant Sciences has a news sentiment score of 1.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Myovant Sciences this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for MYOV on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat Follows6 people have added Myovant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myovant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $192,079.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Myovant Sciences is held by insiders.Percentage Held by InstitutionsOnly 32.55% of the stock of Myovant Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Myovant Sciences are expected to decrease in the coming year, from ($1.45) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myovant Sciences is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myovant Sciences is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MYOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Myovant Sciences (NYSE:MYOV)Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.Read More MYOV Stock News HeadlinesJune 27, 2022 | finance.yahoo.comEnzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric ConditionJune 24, 2022 | americanbankingnews.comCritical Review: Myovant Sciences (NYSE:MYOV) versus Precigen (NASDAQ:PGEN)June 20, 2022 | finance.yahoo.comMyovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?June 17, 2022 | finance.yahoo.comBrand Institute Partners on Brand Name Development for European Commission Approved Treatment for Advanced Hormone-Sensitive Prostate CancerJune 17, 2022 | finance.yahoo.comMyovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated PainJune 16, 2022 | finance.yahoo.comMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08June 16, 2022 | finance.yahoo.comFurther weakness as Myovant Sciences (NYSE:MYOV) drops 15% this week, taking one-year losses to 48%June 6, 2022 | nz.finance.yahoo.comORGOVYX® (relugolix) Now Available from Onco360 for the Treatment of Adult Patients with Advanced Prostate CancerJune 6, 2022 | markets.businessinsider.comPERIOD. BRINGS MENSTRUAL EQUITY ACTION INTO WORKPLACE WITH CORPORATE BENEFITS PROGRAMJune 3, 2022 | finance.yahoo.comMyovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceJune 2, 2022 | markets.businessinsider.comFDA Accepts Myovant Sciences and Pfizer's Filing For Review In Uterine FibroidsJune 2, 2022 | seekingalpha.comU.S. FDA accepts Myovant, Pfizer application seeking expanded approval for MyfembreeMay 16, 2022 | finance.yahoo.comSpirovant Launches State-of-the-Art Laboratory and HeadquartersMay 13, 2022 | finance.yahoo.comUrovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To PlaceboMay 12, 2022 | seekingalpha.comMyovant Sciences Ltd. 2021 Q4 - Results - Earnings Call PresentationMay 11, 2022 | fool.comMyovant Sciences Ltd. (MYOV) Q4 2021 Earnings Call TranscriptMay 10, 2022 | seekingalpha.comMyovant stock rises 25% as Q4 revenue soars Y/Y, partner Pfizer to buy BiohavenMay 10, 2022 | seekingalpha.comMyovant Sciences Ltd. (MYOV) CEO Dave Marek on Q4 2021 Results - Earnings Call TranscriptMay 9, 2022 | finance.yahoo.comMyovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate CancerMay 9, 2022 | seekingalpha.comMyovant in pact with Accord Healthcare to commercialize Orgovyx in EuropeMay 9, 2022 | finance.yahoo.comMyovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in EuropeMay 6, 2022 | nasdaq.comMyovant : FDA Extends Review Of Myfembree In Pain Associated With Endometriosis To August 6May 6, 2022 | marketwatch.comMyovant, Pfizer: FDA Extends Review of Myfembree in Endometriosis >MYOVMay 6, 2022 | seekingalpha.comFDA review for label expansion of Pfizer, Myovant uterine fibroids therapy extendedMay 6, 2022 | finance.yahoo.comALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSIONSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CUSIPN/A CIK1679082 Webwww.myovant.com Phone442074003351FaxN/AEmployees407Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/02/2022Next Earnings (Estimated)7/27/2022Fiscal Year End3/31/2023Price Target and Rating Average Stock Price Forecast$16.67 High Stock Price Forecast$20.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+28.6%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.210010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205.98 million Net Margins-89.18% Pretax Margin-87.00% Return on EquityN/A Return on Assets-32.54% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.92 Sales & Book Value Annual Sales$230.97 million Price / Sales5.35 Cash FlowN/A Price / Cash FlowN/A Book Value($5.04) per share Price / Book-2.57Miscellaneous Outstanding Shares95,332,000Free Float90,470,000Market Cap$1.24 billion OptionableNot Optionable Beta2.78 Myovant Sciences Frequently Asked Questions Should I buy or sell Myovant Sciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Myovant Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOV, but not buy additional shares or sell existing shares. View analyst ratings for Myovant Sciences or view top-rated stocks. What is Myovant Sciences' stock price forecast for 2022? 3 Wall Street analysts have issued twelve-month price targets for Myovant Sciences' shares. Their MYOV stock forecasts range from $12.00 to $20.00. On average, they anticipate Myovant Sciences' share price to reach $16.67 in the next year. This suggests a possible upside of 28.6% from the stock's current price. View analysts' price targets for Myovant Sciences or view top-rated stocks among Wall Street analysts. How has Myovant Sciences' stock performed in 2022? Myovant Sciences' stock was trading at $15.57 on January 1st, 2022. Since then, MYOV shares have decreased by 16.8% and is now trading at $12.96. View the best growth stocks for 2022 here. When is Myovant Sciences' next earnings date? Myovant Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Myovant Sciences. How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd. (NYSE:MYOV) issued its earnings results on Tuesday, May, 10th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.08. The business had revenue of $57.57 million for the quarter, compared to analysts' expectations of $60.76 million. View Myovant Sciences' earnings history. Who are Myovant Sciences' key executives? Myovant Sciences' management team includes the following people: Mr. David C. Marek, CEO & Director (Age 57, Pay $1.31M) (LinkedIn Profile)Mr. Matthew Lang J.D., Gen. Counsel & Corp. Sec. (Age 46, Pay $1.03M) (LinkedIn Profile)Mr. Uneek Mehra, Chief Financial & Bus. OfficerMr. Albert Liao, Director of Corp. CommunicationsMr. Bryan Selby, Sr. VP of Product Devel.Dr. Juan Camilo Arjona Ferreira M.D., Chief Medical Officer (Age 52)Dr. Teresa Perney Ph.D., Sr. VP of Regulatory Affairs & Quality AssuranceDr. Andria Langenberg M.D., Head of Drug Safety & Pharmacovigilance (Age 65)Mr. Jeffrey D. Nornhold, Sr. VP of Pharmaceutical Operations & Devel. (Age 56)Ms. Lauren Merendino, Chief Commercial Officer (Age 47) Who are some of Myovant Sciences' key competitors? Some companies that are related to Myovant Sciences include Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY) and AbCellera Biologics (ABCL). View all of MYOV's competitors. What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL). When did Myovant Sciences IPO? (MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers. What is Myovant Sciences' stock symbol? Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV." How do I buy shares of Myovant Sciences? Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Myovant Sciences' stock price today? One share of MYOV stock can currently be purchased for approximately $12.96. How much money does Myovant Sciences make? Myovant Sciences (NYSE:MYOV) has a market capitalization of $1.24 billion and generates $230.97 million in revenue each year. The company earns $-205.98 million in net income (profit) each year or ($2.210010) on an earnings per share basis. How many employees does Myovant Sciences have? Myovant Sciences employs 407 workers across the globe. How can I contact Myovant Sciences? Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The official website for Myovant Sciences is www.myovant.com. The company can be reached via phone at 442074003351 or via email at investors@myovant.com. This page (NYSE:MYOV) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
